Review




Structured Review

Merck & Co mission sirna universal negative control
A Diagram scheme of the indirect co-culture of C4BPA <t>siRNA-transfected</t> FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.
Mission Sirna Universal Negative Control, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pmc13039365-71-5-13?v=Merck+%26+Co
Average 86 stars, based on 1 article reviews
mission sirna universal negative control - by Bioz Stars, 2026-08
86/100 stars

Images

1) Product Images from "Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment"

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

Journal: Cell Death & Disease

doi: 10.1038/s41419-026-08588-2

A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.
Figure Legend Snippet: A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Techniques Used: Co-Culture Assay, Transfection, Expressing, Cell Culture, Staining, Immunostaining



Similar Products

86
Merck & Co mission sirna universal negative control
A Diagram scheme of the indirect co-culture of C4BPA <t>siRNA-transfected</t> FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.
Mission Sirna Universal Negative Control, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pmc13039365-71-5-13?v=Merck+%26+Co
Average 86 stars, based on 1 article reviews
mission sirna universal negative control - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

86
Merck & Co mission sirna universal negative control 1
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control 1, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pmc12635392-47-0-7?v=Merck+%26+Co
Average 86 stars, based on 1 article reviews
mission sirna universal negative control 1 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
Merck KGaA mission sirna universal negative control #1 sic001
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control #1 Sic001, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pm40497948-43-34-35?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
mission sirna universal negative control #1 sic001 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Merck KGaA sirnas and negative control (mission sirna universal negative control)
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Sirnas And Negative Control (Mission Sirna Universal Negative Control), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pm40139191-293-1-13?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
sirnas and negative control (mission sirna universal negative control) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Millipore mission sirna universal negative control #1
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control #1, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pm40086517-90-0-7?v=Millipore
Average 90 stars, based on 1 article reviews
mission sirna universal negative control #1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Millipore mission sirna universal negative control #2
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control #2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pm39941740-81-0-7?v=Millipore
Average 90 stars, based on 1 article reviews
mission sirna universal negative control #2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Millipore mission sirna universal negative control #2 sic002
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control #2 Sic002, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pmc11815772-65-6-7?v=Millipore
Average 90 stars, based on 1 article reviews
mission sirna universal negative control #2 sic002 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Millipore mission sirna universal negative control #1 sic-001
( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .
Mission Sirna Universal Negative Control #1 Sic 001, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mission+sirna+universal+negative+control/pmc11656513-53-6-7?v=Millipore
Average 90 stars, based on 1 article reviews
mission sirna universal negative control #1 sic-001 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Co-Culture Assay, Transfection, Expressing, Cell Culture, Staining, Immunostaining

( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression.  .

Journal: EMBO Reports

Article Title: Cysteine-reactive covalent chloro- N -acetamide ligands induce ferroptosis mediated cell death

doi: 10.1038/s44319-025-00593-4

Figure Lengend Snippet: ( A ) Pretreatment of OCI-AML2 with ferrostatin-1 for 1 h [10 µM], followed by treatment with EN219 [1 µM], CCW16 [1 µM], or RSL3 [10 µM] for 6 h and measurement of cell viability by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). ( B ) HeLa WT cells were treated either with EN219 [5 µM] or CCW16 [5 µM] for 6 h and analyzed by immunoblotting. The experiment was performed with three biological replicates. Tubulin was used as loading control. ( C ) Quantification of HMOX1 levels shown in ( B ) normalized to tubulin loading control and DMSO control treatment. P values of two-tailed, unpaired Student’s t -tests are indicated; error bars show the standard deviation of the mean, n = 3 (biological replicates). CCW16: p = 0.0102, EN219: p = 0.0018. ( D ) HT-1080 cells stably overexpressing an empty vector or GPX4 WT (GPX4 OE) were treated for 6 h with CCW16/CCW16-based PROTACs [5 µM] or RSL3 as a positive control [1 µM] after treatment with ferrostatin-1 [10 µM] for 1 h. Cell viability was measured by CellTiterGlo. Error bars show the standard deviation of the mean, n = 3 (biological replicates). OE overexpression. .

Article Snippet: MISSION® siRNA Universal Negative Control #1 , Merck , SIC001.

Techniques: Standard Deviation, Western Blot, Control, Two Tailed Test, Stable Transfection, Plasmid Preparation, Positive Control, Over Expression

Journal: EMBO Reports

Article Title: Cysteine-reactive covalent chloro- N -acetamide ligands induce ferroptosis mediated cell death

doi: 10.1038/s44319-025-00593-4

Figure Lengend Snippet: Reagents and tools table

Article Snippet: MISSION® siRNA Universal Negative Control #1 , Merck , SIC001.

Techniques: Recombinant, Sequencing, Negative Control, Protease Inhibitor, Staining, Transfection, Magnetic Beads, Modification, Software, Cell Viability Assay, DC Protein Assay, Bicinchoninic Acid Protein Assay